Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge

mAbs

Volumn 6, Issue 5, 2014, Pages 1255-1264

  Li, Bing ^a   Tesar, Devin ^a   Boswell, C Andrew ^a   Cahaya, Hendry S ^a   Wong, Anne ^a   Zhang, Jianhuan ^a   Gloria, Meng ^a   Eigenbrot, Charles ^a   Pantua, Homer ^a   Diao, Jinyu ^a   Kapadia, Sharookh B ^a   Deng, Rong ^a   Kelley, Robert F ^a  

^a GENENTECH INC   (United States)

Author keywords

Antibody catabolism; Antibody pharmacokinetics; FcRn recycling; Humanized; Isoelectric point

Indexed keywords

HEPATITIS C VIRUS E2 GLYCOPROTEIN ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; INDIUM 111; IODINE 125; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BACULOVIRUS; BINDING AFFINITY; CAPILLARY ISOELECTRIC FOCUSING; CATABOLISM; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ELECTRICAL PARAMETERS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HYDROPHOBICITY; ISOTOPE LABELING; MOLECULE CHARGE; NONHUMAN; PHAGE DISPLAY; RAT; SINGLE DRUG DOSE; SURFACE PLASMON RESONANCE; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VOLUME OF DISTRIBUTION AT STEADY-STATE;

EID: 84913525345     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.29809     Document Type: Article

References (26)

1. Bradley DW. Studies of non-A, non-B hepatitis and characterization of the hepatitis C virus in chimpanzees. Curr Top Microbiol Immunol 2000; 242:1-23; PMID:10592653; http://dx.doi.org/10.1007/978-3-642-59605-6-1
2. Trowbridge R, Gowans EJ. Identification of novel sequences at the 5 0 terminus of the hepatitis C virus genome. J Viral Hepat 1998; 5:95-8; PMID:9572033; http://dx.doi.org/10.1046/j.1365-2893.1998.00090.x
3. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81:1631-48; PMID:10859368
4. Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 2000; 242:55-84; PMID:10592656; http://dx.doi.org/10.1007/978-3-642-59605-6-4
5. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938-41; PMID:9794763; http://dx.doi.org/ 10.1126/science.282.5390.938
6. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21:5017-25; PMID:12356718; http:// dx.doi.org/10.1093/emboj/cdf529
7. Benedicto I, Molina-Jim-enez F, Bartosch B, Cosset FL, Lavillette D, Prieto J, Moreno-Otero R, Valenzuela-Fern-andez A, Aldabe R, L-opez-Cabrera M, et al. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol 2009; 83:8012-20; PMID:19515778; http://dx.doi.org/10.1128/JVI.00038-09
8. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457:882-6; PMID:19182773; http://dx. doi.org/10.1038/nature07684
9. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, W€olk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus coreceptor required for a late step in entry. Nature 2007; 446:801-5; PMID:17325668; http://dx.doi.org/ 10.1038/nature05654
10. Pantua H, Diao J, Ultsch M, Hazen M, Mathieu M, McCutcheon K, Takeda K, Date S, Cheung TK, Phung Q, et al. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol 2013; 425:1899-914; PMID:23458406; http://dx.doi.org/ 10.1016/j.jmb.2013.02.025
11. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 2011; 3:61-6; PMID:20962582; http:// dx.doi.org/10.4161/mabs.3.1.13799
12. Dennis MS. CDR repair: A novel approach to antibody humanization. In: Shire SJ, Gombotz W, Becthold-Peters K, Andya J, eds. Current trends in monoclonal antibody development and manufacturing. New York, New York: Springer, 2010:9-28.
13. H€otzel I, Theil FP, Bernstein LJ, Prabhu S, DengR, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for riskmitigation of antibodies with fast clearance. MAbs 2012; 4:753-60; PMID:23778268; http://dx.doi. org/10.4161/mabs.22189
14. Bumbaca D, Wong A, Drake E, Reyes AE 2nd, Lin BC, Stephan JP, Desnoyers L, Shen BQ, Dennis MS. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 2011; 3:376-86; PMID:21540647; http://dx.doi. org/10.4161/mabs.3.4.15786
15. Vugmeyster Y, Szklut P, Wensel D, Ross J, Xu X, Awwad M, Gill D, Tchistiakov L, Warner G. Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species. Pharm Res 2011; 28:1696-706; PMID:21424161; http://dx.doi.org/10.1007/s11095-011-0405-x
16. Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 2013; 8:e57479; PMID:23468998; http://dx.doi.org/10.1371/journal. pone.0057479
17. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010; 23:385-92; PMID:20159773; http://dx.doi.org/ 10.1093/protein/gzq009
18. Sidhu SS, Lowman HB, Cunningham BC, Wells JA. Phage display for selection of novel binding peptides. Methods Enzymol 2000; 328:333-63; PMID:11075354; http://dx.doi.org/10.1016/S0076-6879(00)28406-1
19. Kelley RF, Meng YG. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function. Methods Mol Biol 2012; 901:277-93; PMID:22723108; http://dx.doi.org/10.1007/978-1-61779-931-0-18
20. Diao J, Pantua H, Ngu H, Komuves L, Diehl L, Schaefer G, Kapadia SB. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J Virol 2012; 86:10935-49; PMID:22855500; http://dx.doi.org/10.1128/ JVI.00750-12
21. H€otzel I, Chiang V, Diao J, Pantua H, Maun HR, Kapadia SB. Efficient production of antibodies against a mammalian integral membrane protein by phage display. Protein Eng Des Sel 2011; 24:679-89; PMID:21810920; http://dx.doi.org/10.1093/protein/ gzr039
22. Martin WL, West AP Jr., Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001; 7:867-77; PMID:11336709; http://dx.doi.org/ 10.1016/S1097-2765(01)00230-1
23. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, Fourie A, Chuh J, Koppada N, Saad O, et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 2011; 22:1994-2004; PMID:21913715; http://dx.doi. org/10.1021/bc200212a
24. Bolton AE, Hunter WM. The labelling of proteins to high specific radioactivities by conjugation to a 125Icontaining acylating agent. Biochem J 1973; 133:529-39; PMID:4733239
25. Boswell CA, Mundo EE, Zhang C, Stainton SL, Yu SF, Lacap JA,Mao W, Kozak KR, Fourie A, Polakis P, et al. Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med 2012; 53:1454-61; PMID:22872740; http:// dx.doi.org/10.2967/jnumed.112.103168
26. Eisenberg D, McLachlan AD. Solvation energy in protein folding and binding. Nature 1986; 319:199-203; PMID:3945310; http://dx.doi.org/10.1038/319199a0